Washington, DC 20006-5349
HELPLINE
Many patients and caregivers want to learn more about the diagnosis, looking to research studies and other data, but these studies are scientific and sometimes hard to read and understand. This session discusses how to read and understand data and studies. This session is presented by:Daniel Sterman, MD, New York University…
Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC). This session is presented by:Jason Foster, MD, University of NebraskaTravis Grotz, MD, Mayo Clinic This is a recording of a session at the 2024 International Symposium on Malignant…
A mesothelioma diagnosis and recurrence monitoring has many facets. Patients, when seeing their oncologists, may hear information about imaging, biopsies, pathology, and biomarkers and genetic analysis. These sessions will focus on each of these areas. These sessions are presented by:Christopher Straus, MD, University of ChicagoAndrea Wolf, MD, Mount SinaiJennifer Sauter, MD,…
These sessions showcase case studies over dual compartment disease and immunotherapy vs. chemotherapy. These sessions are presented by:R. Taylor Ripley, MD, Baylor College of MedicineManish Patel, DO, University of Minnesota This is a recording of a session at the 2024 International Symposium on Malignant Mesothelioma. This symposium is made possible by…
Many mesothelioma patients beat their odds and go on to live rich, fulfilling lives. This panel has three long term patients who discuss the issues that come with survivorship such as long term side effects, survivor guilt, giving back, etc. This panel is moderated by patient, Rich Mosca. Rich is joined…
Mesothelioma is often thought of as a cancer that only affects older men, but that statistic is changing. Many patients are under the age of 50 and more women are getting diagnosed. This change in the demographic of a mesothelioma patient brings up many issues. Younger patients are in the…
A mesothelioma diagnosis affects more than just the patient. The patient’s family members are also heavily influenced taking on a emotional load as well as intense lifestyle changes. This session is a panel focusing on the issues that come up for families when a mesothelioma diagnosis happens. This panel is moderated…
Mental health is a big issue for mesothelioma patients, caregivers, and family members. This session covers how patients as well as their loved ones can prioritize their mental health and deal with the emotional toll of a mesothelioma diagnosis and treatment. This session is presented by:Stephanie Alonso, LCSW, University of Chicago…
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with pemetrexed and platinum-based chemotherapy. Keytruda(pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help…
Mesothelioma has often been classified as a cancer that only affects older people, as the average age of diagnosis for pleural is 72 and peritoneal is 67. This assumption of advanced age being a factor has led to misdiagnosis among younger patients. The demographic of meso patients is consistently changing…
